The 188Re-labeled pegylated nanoliposome (abbreviated as 188Re-Liposome) was prepared and evaluated for its potential as a theragnostic agent for glioma. 188Re-BMEDA complex was loaded into the pegylated liposome core with pH 5.5 ammonium sulfate gradient to produce 188Re-Liposome. Orthotopic Fischer344/F98 glioma tumor-bearing rats were prepared and intravenously injected with 188Re-Liposome. Biodistribution, pharmacokinetic study, autoradiography (ARG), histopathology, and nano-SPECT/CT imaging were conducted for the animal model. The result showed that 188Re-Liposome accumulated in the brain tumor of the animal model from 0.28%±0.09% injected dose (ID)/g (n=3) at 1 hour to a maximum of 1.95%±0.35% ID/g (n=3) at 24 hours postinjection. The tumor-to-normal brain uptake ratio (T/N ratio) increased from 3.5 at 1 hour to 32.5 at 24 hours. Both ARG and histopathological images clearly showed corresponding tumor regions with high T/N ratios. Nano-SPECT/CT detected a very clear tumor image from 4 hours till 48 hours. This study reveals the potential of 188Re-Liposome as a theragnostic agent for brain glioma.
Get full access to this article
View all access options for this article.
References
1.
RaizerJJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol, 2005; 74:77.
2.
ReardonDA, RichJN, FriedmanHSet al.Recent advances in the treatment of malignant astrocytoma. J Clin Oncol, 2006; 24:1253.
3.
MaedaH, WuJ, SawaTet al.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release, 2000; 65:271.
4.
ChoiMR, Stanton-MaxeyKJ, StanleyJKet al.A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett, 2007; 7:3759.
5.
TorchilinVP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 2005; 4:145.
TingG, ChangCH, WangHEet al.Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol, 2010, 10.1155/2010/953537.
8.
KoukourakisMI, KoukourakiS, FezoulidisIet al.High intratumoural accumulation of stealth (R) liposomal doxorubicin (Caelyx (R)) in glioblastomas and in metastatic brain tumours. Br J Cancer, 2000; 83:1281.
9.
HarringtonKJ, MohammadtaghiS, UsterPSet al.Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res, 2001; 7:243.
10.
KhalifaA, DoddsD, RamplingRet al.Liposomal distribution in malignant glioma: Possibilities for therapy. Nucl Med Commun, 1997; 18:17.
11.
OkuN, YamashitaM, KatayamaYet al.PET imaging of brain cancer with positron emitter-labeled liposomes. Int J Pharm, 2011; 403:170.
12.
HsiehBT, LinWY, LuoTYet al.Production of carrier-free Re-188 in the past ten years in Taiwan. J Radioanal Nucl Ch, 2007; 274:569.
13.
HuangFY, HuangLK, LinWYet al.Development of a thermosensitive hydrogel system for local delivery of Re-188 colloid drugs. Appl Radiat Isotopes, 2009; 67:1405.
14.
KnappFF, CallahanAP, BeetsALet al.Processing of reactor-produced W-188 for fabrication of clinical-scale alumina-based W-188/Re-188 generators. Appl Radiat Isotopes, 1994; 45:1123.
15.
BaoA, GoinsB, KlipperRet al.Re-186-liposome labeling using Re-186-SNS/S complexes: In vitro stability, imaging, and biodistribution in rats. J Nucl Med, 2003; 44:1992.
16.
ChenLC, ChangCH, YuCYet al.Biodistribution, pharmacokinetics and imaging of Re-188-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol, 2007; 34:415.
17.
ChenLC, ChangCH, YuCYet al.Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of Re-188-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol, 2008; 35:883.
18.
ChangCH, StabinMG, ChangYJet al.Comparative dosimetric evaluation of nanotargeted Re-188-(DXR)-liposome for internal radiotherapy. Cancer Biother Radiopharm, 2008; 23:749.
19.
ChangYJ, ChangCH, ChangTJet al.Biodistribution, pharmacokinetics and microSPECT/CT imaging of Re-188-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res, 2007; 27:2217.
20.
ChangYJ, ChangCH, YuCYet al.Therapeutic efficacy and microSPECT/CT imaging of Re-188-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol, 2010; 37:95.
21.
ChenMH, ChangCH, ChangYJet al.MicroSPECT/CT imaging and pharmacokinetics of Re-188-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. Anticancer Res, 2010; 30:65.
22.
ZavaletaCL, GoinsBA, BaoAet al.Imaging of Re-186-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis. J Drug Target, 2008; 16:626.
23.
WangSX, BaoA, HerreraSJet al.Intraoperative Re-186-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res, 2008; 14:3975.
24.
SoundararajanA, BaoA, PhillipsWTet al.[Re-186]Liposomal doxorubicin (Doxil): In vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol, 2009; 36:515.
25.
LiuCM, ChangCH, ChangYJet al.Preliminary evaluation of acute toxicity of Re-188-BMEDA-liposome in rats. J Appl Toxicol, 2010; 30:680.
26.
BarthRF, KaurB. Rat brain tumor models in experimental neuro-oncology: The C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol, 2009; 94:299.
27.
MathieuD, LecomteR, TsanaclisAMet al.Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. Can J Neurol Sci, 2007; 34:296.
28.
TsengYL, HongRL, TaoMHet al.Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer, 1999; 80:723.
ChowTH, LinYY, HwangJJet al.Therapeutic efficacy evaluation of In-111-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med, 2009; 50:2073.
34.
PosteG, BucanaC, RazAet al.Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res, 1982; 42:1412.
35.
KemperEM, BoogerdW, ThuisIet al.Modulation of the blood-brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumours?Cancer Treat Rev, 2004; 30:415.
OgiharaI, KojimaS, JayM. Differential uptake of Gallium-67-labeled liposomes between tumors and inflammatory lesions in rats. J Nucl Med, 1986; 27:1300.
38.
PardridgeWM. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technol To, 1999; 2:49.
39.
MamotC, DrummondDC, NobleCOet al.Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res, 2005; 65:11631.
